### Supplementary Table 3. Baseline characteristics of patients with liver cirrhosis grouped according to the COVID-19 infection before case-control matching (n = 13,681)

| Characteristic                              | LC+ COVID+ (n = 67) | LC+ COVID– (n = 6,395) | LC– COVID+ (n = 7,219) | p value |
|---------------------------------------------|---------------------|------------------------|------------------------|---------|
| Male sex<sup>a</sup>                       | 40 (59.7)           | 4,076 (63.7)           | 2,896 (40.1)           | < 0.01  |
| Age, yr<sup>a,b</sup>                      | 59.9 ± 15.7         | 62.3 ± 14.3            | 47.2 ± 18.9            | < 0.01  |
| Region of diagnosis                        |                     |                        |                        |         |
| Daegu & Gyeongbuk<sup>a</sup>              | 43 (64.2)           | 770 (12.0)             | 3,865 (53.5)           | < 0.01  |
| Tested hospital                             |                     |                        |                        |         |
| 3rd<sup>b</sup>                            | 9 (13.4)            | 3,300 (51.6)           | 1,389 (19.2)           | < 0.01  |
| Comorbidities                               |                     |                        |                        |         |
| Decompensated liver cirrhosis<sup>a,b</sup>| 19 (28.4)           | 3,199 (50.0)           | 0                      | < 0.01  |
| Diabetes<sup>a</sup>                        | 21 (31.3)           | 2,488 (38.0)           | 802 (11.1)             | < 0.01  |
| Hypertension<sup>a,b</sup>                 | 27 (40.3)           | 3,645 (57.0)           | 1,714 (23.7)           | < 0.01  |
| Dyslipidemia                                | 19 (28.4)           | 2,320 (36.4)           | 1,584 (21.9)           | < 0.01  |
| Cardiovascular disease                      | 9 (13.4)            | 1,393 (21.8)           | 540 (7.5)              | < 0.01  |
| Cancer<sup>a,b</sup>                        | 12 (17.9)           | 3,022 (47.3)           | 330 (4.6)              | < 0.01  |
| COPD<sup>a</sup>                            | 9 (13.4)            | 1,763 (27.6)           | 726 (10.1)             | < 0.01  |
| Asthma                                      | 12 (17.9)           | 1,472 (23.0)           | 915 (12.7)             | < 0.01  |
| ESRD with dialysis<sup>a</sup>              | 0                   | 387 (6.1)              | 20 (0.3)               | < 0.01  |
| Immunocompromised status<sup>a</sup>        | 9 (13.4)            | 486 (7.5)              | 265 (3.7)              | < 0.01  |
| CCI<sup>a,b</sup>                           | 4.3 ± 2.7           | 6.8 ± 3.8              | 1.4 ± 1.9              | < 0.01  |
| Severe complications<sup>a,b</sup>          | 18 (26.9)           | 1,068 (16.7)           | 686 (9.5)              | < 0.01  |
| Oxygen therapy<sup>a,b</sup>                | 12 (17.9)           | 631 (9.6)              | 574 (7.8)              | < 0.01  |
| Vasopressors<sup>a</sup>                    | 4 (6.0)             | 267 (4.2)              | 97 (1.3)               | < 0.01  |
| Admission for intensive care unit           | 2 (3.0)             | 252 (3.9)              | 116 (1.6)              | < 0.01  |
| Continuous renal replacement therapy        | 1 (1.5)             | 44 (0.7)               | 21 (0.3)               | < 0.01  |
| Death<sup>a</sup>                           | 6 (9.0)             | 501 (7.8)              | 225 (3.1)              | < 0.01  |
| Liver cirrhosis related complications       | 3 (4.5)             | 524 (8.2)              | -                      | 0.37    |
| Varix                                       | 2 (3.0)             | 195 (3.1)              | -                      | 1.00    |
| Ascites                                     | 2 (3.0)             | 350 (5.5)              | -                      | 0.59    |
| Hepatorenal syndrome                       | 0                   | 64 (1.0)               | -                      | 1.00    |
| Spontaneous bacterial peritonitis           | 0                   | 11 (0.2)               | -                      | 1.00    |
| Encephalopathy                             | 3 (4.5)             | 233 (3.6)              | -                      | 0.74    |

Values are presented as number (%) or mean ± standard deviation.

COVID-19, coronavirus disease 2019; LC, liver cirrhosis; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; CCI, Charlson comorbidity index.

<sup>a</sup>p < 0.05 between LC+ COVID+ and LC– COVID+.

<sup>b</sup>p < 0.05 between LC+ COVID+ and LC+ COVID–.